Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

v3.8.0.1
Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Disaggregation of Revenue
The following table presents net revenues disaggregated by type (in thousands):

 
 
For the period ended
 
 
March 31, 2018
 
March 31, 2017
Prescribed dietary supplements
 
$
2,231

 
$

Prescription drugs
 
2,029

 

Sales force revenue
 
223

 

Grant revenue
 

 
384

Total revenue
 
$
4,483

 
$
384